Tevogen Bio Holdings (TVGN) said Tuesday it has signed a letter of intent with CD8 Technology Services to build up to a $50 million facility for research and development and manufacturing.
Tevogen said the project will not impact shareholder equity.
The company's shares were down 7.9% in recent trading.
Price: 2.53, Change: -0.22, Percent Change: -7.85
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。